Founded in 2022, Aisthesis Medical develops hospital-grade clinical decision-support tools that leverage multimodal data, digital-twin technology and explainable AI. Its flagship product, VIOSync Sepsis Prediction Index (SPI), securely ingests patient data from hospital systems to forecast the likelihood of sepsis within the next 48 hours and surfaces the key physiological drivers behind the risk score. The company targets a critical clinical need, as sepsis causes more than 11 million deaths annually and often goes undetected until deterioration occurs. Recent funding is being directed toward CE MDR regulatory submission, expanded clinical validation studies across leading UK and EU hospitals, and team growth ahead of NHS and international pilot rollouts. Aisthesis partners with ICU clinicians—including NHS consultant Dr. Savvas Vlachos—to ensure the platform fits real-world workflows. The founding team holds AI doctorates from institutions such as Imperial College London and ETH Zurich and is supported by a network of industry advisors. Although still pre-revenue, the company aims to become the standard for proactive sepsis prevention in hospitals worldwide.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2025